The Committee for Medicinal Products for Veterinary Use (hereinafter ‘CVMP’) recommended establishing a provisional MRL for tildipirosin for bovine species, applicable to muscle, fat, liver and kidney, excluding animals producing milk for human consumption. The provisional MRL set out for muscle should not apply to the injection site, where residue levels should not exceed 11500 μg/kg.
Recital 4, Commission Regulation (EU) No 759/2010 of 24 August 2010 amending the Annex to Regulatio…
In forcesince 24 Aug 2010